CNBC Closing Bell
2026-08-20 · Hosted by Scott Wapner, Melissa Lee, Michael Santoli · CNBC
Executive Summary
Treasury Secretary Scott Bessent announced the Treasury would double its long-dated bond buyback program, pulling 30-year yields down from near two-decade highs and sending a broad rally through equal-weighted stocks, defensives, and materials, even as chip stocks lagged. Bond strategist Rick Santelli and Fortress's Elizabeth Burton debated whether the move can durably anchor yields, with Burton warning it could ultimately prove inflationary as the money supply expands. Meanwhile Moderna surged nearly 180% (adding roughly $44 billion in market cap) after its personalized melanoma vaccine, developed with Merck's Keytruda, hit its primary endpoint in a Phase 3 trial — a result Bernstein's Courtney Breen called validation that Moderna's mRNA platform extends beyond respiratory vaccines, though she cautioned the individualized-manufacturing model limits operating margins (profit per dollar of sales) versus a mass-market drug.
Key Stories & Changes
1. Treasury's Bond Buyback Doubling and Yield Relief Rally
Treasury will roughly double debt buybacks: seven operations from September to November, potential total rising from $14 billion to $28 billion
30-year yield had been near 2007 highs; move brought yields down and lifted equal-weighted S&P (RSP) to a new high
Fed Chair Kevin Worsh wants markets to self-correct without intervention — creating what Rick Santelli called an "interesting dichotomy" with Treasury Secretary Bessent's active market intervention
Bond strategist Elizabeth Burton (Fortress) warned the move could prove inflationary via an expanding money supply, and flagged rising hedging costs for pension/insurance investors with long-duration liabilities
2. Moderna-Merck Cancer Vaccine Breakthrough
MRNA: Moderna — +180% (~$44B market cap added) — Phase 3 melanoma vaccine + Keytruda beat Keytruda alone on recurrence/spread
MRK: Merck — Record high — Combination therapy could extend Keytruda's relevance ahead of 2028 patent cliff
Bernstein's Courtney Breen noted roughly 15% of Moderna's float was short, contributing to a squeeze
Peak sales estimate for the melanoma indication alone: ~$1.2 billion; broader pipeline includes lung, bladder, kidney, gastric and pancreatic cancer trials
Breen cautioned the individualized production process (patient biopsy → 6-week custom formulation) limits margin scalability versus an off-the-shelf drug like Keytruda
The combination does not co-formulate with Keytruda, so it does not shield Merck from Keytruda's patent cliff/biosimilar risk on the IV product, though subcutaneous Keytruda faces less near-term biosimilar competition
3. OpenAI vs. Anthropic Revenue and Profitability Gap
OpenAI Q2 revenue: $6.7 billion, up only 18% quarter-over-quarter; operating loss widened to $12.3 billion
Anthropic Q2 revenue: $11.6 billion (more than doubled), with a $65 billion annualized run-rate versus OpenAI's $40 billion, and a small operating profit of $559 million
Plexo Capital's Low Tony noted OpenAI's growth rate trails public comps like CoreWeave, Palantir, and Micron; OpenAI valued at $852 billion (~32x annualized Q2 revenue) versus Anthropic's $1.2 trillion valuation (~18.5x)
OpenAI enterprise revenue reportedly approaching 40% of total, suggesting a possible inflection as Codex gains traction
4. Data Center Political Backlash Spreads
New York issued the first state moratorium on data center buildouts roughly a month ago; nearly the entire East Coast is now considering similar bans
Pennsylvania Governor Josh Shapiro signed an executive order against "predatory backers and bad proposals," raising his profile as a 2028 Democratic presidential contender
Data centers are surfacing in the Ohio Senate race (Sherrod Brown ad) and Texas governor's race (Gina Hinojosa vs. Greg Abbott)
Anchors noted roughly 1,000 data centers are currently under construction, with OpenAI and Anthropic revenue projections predicated on that capacity being built; a 15% shortfall in completed projects could meaningfully raise financing costs
5. Target and Retail Earnings Ahead of Walmart
Target shares rose to their highest close in two years after beating on top and bottom lines and raising full-year guidance, helped by tariff refunds and stronger same-store sales
Goldman's Kate McShane rates Walmart over Target but called Target's print a genuine "further proof point" of its turnaround; apparel and home categories were flat and remain a weak spot
Walmart expects roughly $3 billion in tariff refunds, some directed toward price investment, particularly in grocery (60% of Walmart's sales vs. 40% for Target)
6. Unitree Robotics' Shanghai Debut and China's Physical AI Lead
Unitree Robotics stock surged 460% on its Shanghai debut (up sixfold from its $22 IPO price); retail tranche was 5,500x subscribed
Shipped roughly 5,500 robots last year versus Tesla's zero for Optimus; combined with Shanghai-based Agibot, Chinese firms hold over 70% global humanoid robot market share
Backed by state entities and considered a strategic sector by Beijing; Morgan Stanley expects China's pilot projects to shift to broader deployment in H2 2026
7. Diesel Prices and Refining Margins Surge
California diesel hit $7 a gallon, close to April highs, driven by offline Russian refining capacity, US refinery maintenance, and low European river levels limiting barge fuel shipments
Refining stocks have more than doubled since the start of the year on record crack spreads (the profit margin refiners earn turning crude into fuel)
A relief pipeline project (Western Gateway, tied to Kinder Morgan, Philip 66, HF Sinclair) is not projected to open until 2029
Trends Identified
1. Treasury Intervention as a De Facto Yield Cap
The Treasury's buyback doubling functions similarly to the Fed's 2011 "Operation Twist," effectively capping long-end yields ahead of the midterms. Guests were split on durability — some saw it as a genuine liquidity fix, others as papering over unresolved deficit and inflation pressures — but the immediate market reaction (broad-based rally, weaker dollar) was unambiguous.
2. Healthcare/Biotech Rotation Gains Momentum
The Moderna-Merck breakthrough triggered sector-wide gains beyond the two stocks directly involved, reflecting a broader rotation into healthcare that had been building for months. This adds to a pattern where capital increasingly seeks value and defensive plays alongside continued AI enthusiasm, rather than purely chasing momentum names.
3. AI Leader Divergence: Anthropic's Enterprise Edge
The widening profitability and growth gap between OpenAI and Anthropic centers on enterprise penetration — Anthropic went "straight to enterprise" with tools like Claude Code, while OpenAI remained consumer-weighted longer. This divergence is shaping how investors will price both companies' impending IPOs.
4. Data Center Backlash Becomes a Midterm Election Issue
What began as local zoning disputes has become a bipartisan political flashpoint, intersecting with affordability concerns ahead of the midterms. The risk is no longer purely local — potential project delays could raise financing costs and compress the return on investment for the trillion-dollar AI capex (capital expenditure, i.e. spending on physical infrastructure) pipeline.
5. Tariff Refunds as a Retail Earnings Tailwind
Target and expected Walmart results are benefiting from tariff refund flows being redirected into consumer price investment, a dynamic panelists flagged as possibly short-lived once refund flows normalize, especially against a backdrop of elevated gas and mortgage costs pressuring consumers. ---
Sentiment Analysis
Overall Market Sentiment: Broadly Bullish, Rate-Sensitive
Equities rallied on yield relief and healthcare euphoria, but panelists flagged skepticism about the durability of the Treasury intervention and rising AI-related financing risk.
Risk Factors Highlighted
Inflationary side effects of Treasury intervention: Guests warned an expanding money supply used to fund buybacks could stoke inflation.
Fiscal/monetary policy tension: An apparent contradiction between Fed Chair Worsh's hands-off stance and Treasury Secretary Bessent's active market intervention.
AI capex financing exposure: Rising credit spreads (e.g., Blackstone QTS pricing investment-grade debt at high-yield levels) as hyperscalers issue more debt.
Data center political backlash: Potential 15%+ project shortfall could raise financing costs and delay AI revenue realization for OpenAI and Anthropic.
OpenAI's widening losses: $12.3 billion quarterly operating loss and slower revenue growth versus Anthropic and public AI-adjacent comps.
Moderna valuation overreach risk: Analyst flagged the $40–50 billion market cap gain as pricing in more than the current data supports.
Merck's Keytruda patent cliff: The new therapy adds on to, rather than co-formulates with, Keytruda, leaving IV biosimilar exposure largely intact by 2028.
Elevated diesel and fuel costs: $7/gallon diesel in California raises broader inflation risk via trucking, shipping, and agricultural costs.
Consumer affordability strain: High gas prices and still-elevated mortgage rates could undercut the durability of tariff-refund-driven retail earnings beats.
This episode was covered in today's [The Market Signal — 2026-08-20](https://marketsignal.beehiiv.com/p/the-market-signal-2026-08-20), a cross-source synthesis of multiple podcast reports.